HCPCS Level II code J1569 denotes a 500 mg vial of non-lyophilized immune globulin (Gammagard liquid) used for therapeutic immune globulin administration. This code is nationally relevant as immune globulin therapies are widely used for primary and secondary immunodeficiencies, certain autoimmune disorders, and other indications where passive immunity is provided. Accurate coding for these products affects billing clarity, inventory tracking, and patient cost-sharing across payers.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for utilization and coverage patterns, an overview of billing and site-of-service implications, and context on clinical usage of liquid immune globulin formulations. The publication outlines common modifiers and claims considerations associated with administering an infused biologic, and highlights areas where policy updates or payer-specific rules frequently affect reimbursement and documentation.

This summary is intended for national audiences including billing professionals, clinical administrators, and policy analysts seeking concise guidance on how HCPCS Level II code J1569 is used in practice, what to expect in payer interactions, and where to focus documentation to support claims adjudication.